No Data
No Data
Express News | Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $90 Price Target
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
11 Compounder Opportunities According to Goldman: AMD, BDX, INFA
BofA Securities Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $101
J.P. Morgan Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating
Biomarin Pharmaceutical To Present At Evercore ISI HealthCONx Conference; Webcast At 10:00 AM ET